The life science sector is trying to localize their supply chain and reduce the dependency on other countries.
FREMONT, CA: The life science sector is going through immense changes and disruption. Moreover, the industry companies are also moving towards localization because it does not want to depend on other countries to gain some benefit. The companies are also focusing on the supply chain's security because they are slowly decreasing their dependency on outsourcing it to other countries to get the cost advantage.
The localization of the life science sector
Localizing in the life science sector is not a new concept, but it is increasing in recent times. The life science companies are looking forward to bringing back elements of products in their local markets. It is also necessary for them to develop a presence in the worldwide market.
However, the large pharma, medical device, or biotech organizations have to increase their capabilities to meet the local market's requirements to develop drug security with full production and distribution locally. Although it is virtually impossible to decrease the dependency on well-established trading relationships overnight, the companies are trying their best.
It might take the life science companies months or years to stop utilizing their API supplier or move a drug to a local manufacturing center.
The companies can also increase their capabilities to discretely serve the local markets even while utilizing a global supply model where it seems accurate. The outcome might not end the global supply chains, but it will develop a multi-layered ecosystem with the small local supply chains connected to a worldwide backbone for the large companies. However, it will be necessary to apply a new supply chain visibility, communication, and collaboration level.
The growth of CDMOs
During the pandemic of COVID-19, one sector of the life science has witnessed extreme growth, and it is the Contract Development and Manufacturing Organization (CDMO) market. it is also estimated that CDMOs change will increase in the future.
The life science companies have increased their partnering with CDMOs because of the high demand for production to meet objectives like localization while prioritizing cost and revenue. Many governments are also trying to incentivize the utilization of CDMOs to drive the country's production. Therefore, the organizations will increase their investment in CDMOs to accelerate their presence in the global market at a reduced cost.